Современные возможности лечения больных диссеминированным колоректальным раком: II линия лекарственной терапии -


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В статье представлены клинические данные по современным возможностям лечения метастатического колоректального рака во II линии терапии. Дан подробный анализ эффективности и токсичности используемых комбинаций химиопрепаратов. Представлены результаты изучения таргетных препаратов во II линии терапии в комбинации с цитостатиками и в монотерапии. Проанализирована роль таргетной терапии и ее место в лечении диссеминированного колоректального рака.

Полный текст

Доступ закрыт

Об авторах

К. А Воронцова

ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России

врач-онколог отделения химиотерапии и комбинированного лечения злокачественных опухолей ФГБУ Москва

Н. В Доброва

ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России

к.м.н., с.н.с. отделения химиотерапии и комбинированного лечения злокачественных: опухолей ФГБУ Москва

Г. В Вышинская

ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России

д.м.н., в.н.с. отделения химиотерапии и комбинированного лечения злокачественных: опухолей ФГБУ Москва

Список литературы

  1. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. JCO. 1998;16:1301-08.
  2. Thirion P., Michielis S., Pignon J.P., Buyse M., Braud A.C., Carlson R.W., O'Connell M., Sargent P., Piedbois P.; Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an update meta-analysis. J. Clin. Oncol. 2004;22(18):3766-75.
  3. Cocconi G., Cunningham D., Van Cutsem E., Francois E., Gustavsson B., van Hazel G., Kerr D., Possinger K., Hietschold S.M. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. JCO. 1998;16:2943-52.
  4. Sato A, Kurihara M., Horikoshi N. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group. Anticancer Drugs. 1999; 10(8):741 -48.
  5. Desrame J., Dourthe L.-M., Debourdeau P., Mille D., Artru P., Albrand H. Raltitrexed in the management of metastatic colorectal cancer: The COMET study. J. Clin. Oncol. (Meeting Abstracts). 2015;33(3 suppl. 677).
  6. Rothenberg M.L., Oza A.M., Bigelow R.H., Berlin J.D., Marshall J.L., Ramanathan R.K., Hart L.L., Gupta S., Garay C.A., Burger B.G., Le Bail N., Haller D.G. Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial. JCO. 2003;21(11): 2059-69.
  7. Andre T., Bensmaine M.A.,Louvet C.,Francois E., Lucas V., Desseigne F., Beerblock K., Bouche O., Carola E., Merrouche Y., Morvan F., Dupont-Andre G., de Gramont A. Multicentrer phase II study of bimonthly high dose leucovo-rin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leuco-vorin and fluorouracil regimen. J. Clin. Oncol. 1999;17:3560-68
  8. Vyzula R., Kocakova I., Demlova R., Kiss I., Dusek L., Jarkovsky J. Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer. Neoplasma. 2006;53(2):119-27.
  9. Van Cutsem E., et al. Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer. ECCO 11, 2001:abstr 1008.
  10. Comella P., Casaretti R., Crucitta E., De Vita F., Palmeri S., Avallone A., Orditura M., De Lucia L., Del Prete S., Catalano G., Lorusso V., Comella G. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br. J. Cancer. 2002;86(12):1871-75.
  11. Cunningham D., Glimelius B. A phase III study of irinotecan (CPT-11 ) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol. 1999;26(1 Suppl. 5);6-12.
  12. Rougier P., Van Cutsem E., Bajetta E., Nie-derle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., Jacques C. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1407-12.
  13. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de Gramont A. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J. Clin.l Oncol. 2004;22(2): 229-37.
  14. Bajetta E., Beretta E., Di Bartolomeo M., Cortinovis D., Ferrario E., Dognini G., Toffolatti L., Buzzoni R. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. Oncology. 2004;66(2):132-37.
  15. Haller D.G., Rothenberg M.L., Wong A.O., et al. Final results of a randomized phase III trial comparing irinotecan+oxaliplatin (IROX) to irinotecan monotherapy in patients with metastatic colorectal cancer (MCRC) previously treated with fluoropyrimidines. Ann. Oncol. 2004;15(suppl. 3):2630.
  16. Rougier P., Lepille D., Bennouna J., Marre A., DucreuxM.,MignotL.,Hua A.,Mery-MignardD. Antitumor activity of three second-line treatment combinations with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomized, multicenter phase II trial. Ann. Oncol. 2002;13:1558-67.
  17. Rothenberg M.L., Cox J.V., Butts C., Navarro M., Bang Y.-J.,Goel R.,Gollins S.,Siu L.L., Laguerre S., Cunningham D. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann. Oncol. 2008;19:1720-26.
  18. Manzano J.L., Diaz N., Rolfo C., Juez I., Gracia-Bueno J.M., Gonzaez M.L., Queralt B., Losa F., Martin C., Abad A. Phase II comparative study of capecitabine combined with oxaliplatin (XELOX) and CPT-11 (XELIRI) for advanced colorectal cancer patients (p) previously treated with 5-FU-based chemotherapy. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2007;25(18S):14544
  19. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., Schwartz M.A., Benson A.B. 3rd. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007; 20:1539-44.
  20. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003;21:60.
  21. Masi G., Salvatore L., Boni L., Loupakis F., Cremolini C., Fornaro L., Schirripa M., Cupini S., Barbara C., Safina V., Granetto C., Fea E., Antonuzzo L., Boni C., Allegrini G., Chiara S., Amoroso D., Bonetti A., Falcone A.; on behalf of the BEBYP Study Investigators. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYPtrial. Ann. Oncol. 2015:mdv012.
  22. Wang T.-F, Lockhart A.C. Aflibercept in the Treatment of Metastatic Colorectal Cancer. Clin. Med. Insights Oncol. 2012;6:19-30.
  23. Tang P.A., Cohen S.J., Kollmannsberger C., Bjarnason G., Virik K., MacKenzie M.J., Lourenco L., Wang L., Chen A., Moore M.J. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clin. Cancer Res. 2012;18:6023.
  24. VanCutsem E.,Tabernero J.,Lakomy R.,Prenen H., Prausova J, Macarulla T., Ruff P., van Hazel G.A., Moiseyenko V., Ferry D., McKendrickJ., PolikoffJ., Tellier A., Castan R., Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012;30(28): 3499-506.
  25. Ruff P., Ferry D.R., Lakomy R., Prausova J., van Hazel G.A., Hoff P.M.,Cunningham D.,Arnold D., Schmoll H.J, Moiseyenko V.M., McKendrick J.J., ten Tije A.J., Vishwanath R.L., Bhargava P., Chevalier S., Macarulla T., van Cutsem E. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur. J. Cancer. 2015;51:18-26.
  26. Tabernero J., Cohn A. L., Obermannova R., Bodoky G., Garcia-Carbonero R., Ciuleanu T.-E., Portnoy D.C., van Cutsem E., Grothey A., Prausova J., Garcia-Alfonso P., Yamazaki K., Clingan P.R., Zagonel V., Kim T.W., Simms L., Chang S.-C., Nasroulah F., Yoshino T.; the RAISE Study Investigators. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J. Clin. Oncol. (Meeting Abstracts). 2015;3 3(3 suppl. 512).
  27. Cunningham D., Humblet Y., SienaS., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinitecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004;351(4):337-45.
  28. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., Vega-Villegas M.E., Eng C., Steinhauer E.U., Prausova J., Lenz H.J., Borg C., Middleton G., Kröning H., Luppi G., Kisker O., Zubel A., Langer C., Kopit J., Burris.H.A. 3rd. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26(14).
  29. Di Fiore F., Van Cutsem E., Laurent-Puig P., Siena S., Frattini M., De Roock W., Lievre A., Sartore-Bianchi A., Bardelli A., Tejpar S. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series. ESMO 2008.
  30. DeRoockW.,ClaesB.,BernasconiD.,DeSchutterJ., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753-62.
  31. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008;26(35): 5705-12.
  32. Kopetz S., McDonough S., Van Karlyle Morris, Lenz H.-J., Magliocco A.M., Atreya C.E., Diaz L.A., Allegra C.J., Lieu C.H., Eckhardt S.G., Semrad T.J., Kaberle K., GuthrieK.,HochsterH.S. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastaticcolorec-tal cancer (mCRC). J. Clin. Oncol. (Meeting Abstracts).2015;33(3 suppl. TPS790).
  33. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., Andre T., Chan E., Lordick F., Punt C.J., Strickland A.H., Wilson G., Ciuleanu T.E., Roman L., Van Cutsem E., Tian Y., Sidhu R. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann. Oncol. 2014;25(1):107-16.
  34. Van Hellemond I.E., Creemers G.J., van Warmerdam L.J., de Jong F.A., Koornstra R.H. Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience. Clin. Oncol. (R. Coll. Radiol.) 2014;26(3): 135-41.
  35. Komatsu Y., Yuki S., Nakatsumi H., Hosokawa A., Nakamura M., Muto O., Meguro T., Iwanaga I., Hatanaka K., Tsuji Y., Sato A., Eto K., Furukawa K., Onodera M., Tateyama M., Takahashi Y., Dazai M., Yokoyama S., Honda T., Sakata Y., HGCSG. Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/ Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment. J. Clin. Oncol. (Meeting Abstracts) 2015; 33(3 suppl. 746).
  36. Shimoyama R., Kimura T., Takaoka T., Sakamoto K., Kawamoto S., Yoshizaki K., Negoro Y., Goda F., Tsuji A., Nakayama T., Miyamoto H., Takayama T., Niitsu Y. A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRASmetastatic colorectal cancer. J. Clin. Oncol. (Meeting Abstracts) ■ 2015;33(3 suppl. 732)
  37. Liang H.L., Hu A.P., Li S.L., Liu J.Y. Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. Med. Oncol. 2014;31(6):976.
  38. Townsend A., Tebbutt N., Karapetis C.S., Cooper P., Singhal N., Yeend S., Pirc L., Price T.J. A Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer (MCRC) with KRAS Wild Type (WT). Ann. Oncol. 2014;25(suppl. 4):183.
  39. Hecht J.R., Reid T.R., Garrett C.R., Beck J.T., Davidson S.J.,MackenzieM.J, Brandt U., Rizvi S., Sharma S. Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer. Anticancer Res. 2015;35(3):1567-73.
  40. Cohn1 A.L., Tabernero J., Maure lJ., Nowara E., Sastre J., Chuah B. Y.S.,Kopp M. V.,Sakaeva D.D., Mitchell E.P., Dubey S., Suzuki S., Hei Y.-J., Galimi F., McCaffery I., Pan Y., Loberg R., Cottrell S.,Choo S.-P. A randomized, placebocontrolled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann. Oncol. 2013;24(7):1 777-85.
  41. Hochster H.S., Messersmith W.A., O'Neil B.H., Groshen S.G., Lenz H.-J., Cohen D.J., Denlinger C.S., Gold P.J., Eckhardt S.G., Locker G.Y., Ames P., McKinley M., Leichman L.P., Academic GI Cancer Consortium (AGICC). The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC). J. Clin. Oncol. (Meeting Abstracts) 2013;31(15 suppl. 3587).
  42. Bridgewater J.A., Cervantes A., Markman B., Siena S., Cubillo A., Garcia-Carbonero R., Sigal D., Aprile G., Cunningham D., Nadal C., Pericay C., Samuel L.M., Hochhauser D., Perez-Fidalgo J.A., Strickland A., Guizani C., Golding S., Lopez-Valverde V., Ott M.G., Tabernero J. GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectalcancer (mCRC). J. Clin. Oncol. (Meeting Abstracts) 2015;33(3 suppl. 669).
  43. Peeters M., Strickland A.H., Lichinitser M., Suresh A.V.S., Manikhas G., Shapiro J., Rogowski W., Huang X., Wu B., Warner D., Jain R., Tebbutt N.C. A randomised, doubleblind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br. J. Cancer. 2013;108(3):503-11.
  44. Hoehler T., Decker T., Schimanski C., Schmitz S.H., Kanzler S., Rauh J., Vehling-Kaiser U., Bernhard H., Hoffmann T., Niederle N., von Verschuer U., von Wichert G., Wagner T. Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-linemetastatic colorectal carcinoma (mCRC) treatment. J. Clin. Oncol. (Meeting Abstracts). 2013;31(15 suppl. 3586).

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах